Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15922741 | 0.97 | TP53 (0.39) | TP53MAPK1SMN1; SMN2ATMGAA | |
| SCHEMBL11355878 | 0.92 | HSD11B1 (0.41) | TP53MAPK1SMN1; SMN2ATMHSD11B1 | |
| SCHEMBL15922897 | 0.92 | TP53 (0.41) | TP53MAPK1SMN1; SMN2ATMGAA | |
| SCHEMBL10436532 | 0.90 | HSD11B1 (0.43) | TP53SMN1; SMN2GAAHSD11B1L3MBTL1 | |
| SCHEMBL15922928 | 0.90 | HSD11B1 (0.43) | TP53SMN1; SMN2GAAHSD11B1L3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL27892508 | 0.85 | HSD11B1 (0.41) | TP53SMN1; SMN2GAAHSD11B1L3MBTL1 | |
| SCHEMBL455945 | 0.81 | TP53 (0.36) | TP53MAPK1SMN1; SMN2ATMGAA | |
| SCHEMBL19073248 | 0.80 | TP53 (0.36) | TP53MAPK1SMN1; SMN2ATMGAA | |
| SCHEMBL18177915 | 0.80 | HTT (0.47) | TP53MAPK1SMN1; SMN2ATMGAA | |
| Hydrochloric Acid SCHEMBL1697515 | 0.79 | SMN1; SMN2 (0.38) | TP53MAPK1SMN1; SMN2ATMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884097-B2 | Contains 1-(2-Aminoethyl)piperidine and 2-adamantanone; mycobacterial infections | SEQUELLA, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-1670314-A4 | METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS | SEQUELLA INC (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1670314-A2 | METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS | Sequella, Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050113574-A1 | Methods and compositions comprising diamines as new anti-tubercular therapeutics | SEQUELLA, INC. | 2005-05-26 | — | — | US | disclosed |
| WO-2005034857-A2 | METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS | SEQUELLA, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113574-A1 | Methods and compositions comprising diamines as new anti-tubercular therapeutics | C5, DDC, SAT1 | TP53 1956/4885MAPK1 1865/4885SMN1; SMN2 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.